Imidapril: A review of its use in essential hypertension, type 1 diabetic nephropathy and chronic heart failure

Drugs

Volumn 67, Issue 9, 2007, Pages 1359-1378

  Robinson, Dean M ^a   Curran, Monique P ^a   Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IMIDAPRIL; IMIDAPRILAT; LOSARTAN; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

AREA UNDER THE CURVE; BRONCHITIS; CLINICAL TRIAL; COUGHING; DIABETIC NEPHROPATHY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ESSENTIAL HYPERTENSION; EXERCISE; FLUSHING; HEART FAILURE; HUMAN; INDUCED HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LARYNX DISORDER; NAUSEA; NONHUMAN; PHARYNX DISCOMFORT; POSTMARKETING SURVEILLANCE; POTASSIUM BLOOD LEVEL; RENAL PROTECTION; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SODIUM RETENTION; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; VASODILATATION; WATER RETENTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; IMIDAZOLIDINES; MOLECULAR STRUCTURE; TREATMENT OUTCOME;

EID: 34249944131     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767090-00008     Document Type: Review

References (90)

1. Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet 2002; 41 (3): 207-24
2. World Health Organization. The World Health Report 2002: reducing risks, promoting healthy life [online]. Available from URL: http://www.who.int/whr/ 2002/en/index.html [Accessed 2006 Jul 28]
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 Apr 7; 335 (8693): 827-38
4. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology [online]. Available from URL: http://escol.escardio.org/ [Accessed 2006 Aug 9]
5. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 Sep 20; 112 (12): e154-235
6. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care 2004 Jan; 27 Suppl. 1: S79-83
7. TANATRIL® tablets 2.5 and 5mg (imidapril hydrochloride); Japanese prescribing information (English version). Osaka: Tanabe Seiyaku Co. Ltd, 2005 Jun
8. Dews I, VandenBurg M. A 24-week dose-titration study of the angiotensin-converting enzyme inhibitor imidapril in the treatment of mild-to-moderate essential hypertension in the elderly. J Int Med Res 2001 Mar-Apr, 100-7
9. Data on File. Tanabe Seiyaku Co. Ltd, 2007
10. Summary of product characteristics: Tanatril 5 mg tablet. Tanabe Europe N.V., 2002 Nov 11
11. Oshima S, Ogawa H, Mizuno Y, et al. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J 1997 Nov; 134 (Pt 1): 961-6
12. Harder S, Thürmann PA. Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Br J Clin Pharmacol 1997 May; 43: 475-80
13. Kubo M, Kato J, Ochiai T, et al. Pharmacological studies on (4S)-1-methyl-3-{(2s)-2-[n-((1s)-1-ethoxycarbonyl-3-phenyl-propyl) amino]propionyl}-2-oxo-imidazolidine-4-carboxylic acid hydrochloride (TA-6366), a new ACE inhibitor: I. ACE inhibitory and antihypertensive activities. Jpn J Pharmacol 1990; 53: 201-10
14. Kubo M, Ochiai T, Kato J, et al. Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs). Jpn J Pharmacol 1991; 57: 517-26
15. VandenBurg MJ, Mackay EM, Dews I, et al. Dose finding studies with imidapril: a new ACE inhibitor. Br J Clin Pharmacol 1994 Mar; 37: 265-72
16. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998 Dec; 32: 1811-8
17. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001 Jan-Feb; 29 (1): 13-21
18. Shah NC, Pringle S, Struthers A. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. J Renin Angiotensin Aldosterone Syst 2006; 7 (1): 20-30
19. Kohno I, Ijiri H, Takusagawa M, et al. Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration. Chronobiol Int 2000; 17 (2): 209-19
20. Huang PJ, Chien KL, Chen MF, et al. Efficacy and safety of imidapril in patients with essential hypertension: a double-blind comparison with captopril. Cardiology 2001; 95 (3): 146-50
21. Saruta T, Omae T, Kuramochi M, et al. Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control. J Hypertens 1995 Sep; 13 Suppl. 3: S23-30
22. van der Does R, Euler R. Comparison of the antihypertensive effect of imidapril and enalapril in the treatment of mild to moderate essential hypertension: a randomized, double-blind, parallel-group study. Curr Ther Res Clin Exp 2001 Jun; 62: 437-50
23. van der Does R, Euler R. A randomized, double-blind, parallel-group study to compare the anti-hypertensive effects of imidapril and nifedipine in the treatment of mild-to-moderate essential hypertension. J Int Med Res 2001 May-Jun; 29: 154-162
24. Dews I, VandenBurg M. A 52-week, open-label, dose-titration safety study of imidapril in the treatment of mild to moderate hypertension. Curr Ther Res Clin Exp 2001 Feb; 62: 167-76
25. Demolis P, Annane D, Duhaze P, et al. Systemic, regional and cerebral hemodynamic effects of a new angiotensin converting enzyme inhibitor, imidapril, in healthy volunteers. Fundam Clin Pharmacol 1994; 8 (1): 80-9
26. Pinto YM, van Veldhuisen DJ, Tjon-Ka-Jie RT, et al. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Eur J Clin Pharmacol 1996 Jun; 50: 265-8
27. Hirata Y, Hayakawa H, Kakoki M, et al. Nitric oxide release from kidneys of hypertensive rats treated with imidapril. Hypertension 1996; 27: 672-8
28. Suda O, Tsutsui M, Morishita T, et al. Long-term treatment with imidapril but not with nifedipine enhances plasma NOx con-centration in patients with essential hypertension. J Pharmacol Sci 2006 Jun; 101 (2): 159-65
29. Higashi Y, Oshima T, Sasaki S, et al. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculture to L-arginine in patients with essential hypertension. Hypertension 1998 Jul; 32: 16-24
30. Higashi Y, Sasaki S, Nakagawa K, et al. Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol 2001 Mar 1; 37 (3): 863-70
31. Higashi Y, Sasaki S, Nakagawa K, et al. Severity of hypertension affects improved resistance artery endothelial function by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 2002 May; 39 (5): 668-76
32. Higashi Y, Sasaki S, Nakagawa K, et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol 2000 Feb; 35 (2): 284-91
33. Chen R, Iwai M, Wu L, et al. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension 2003 Oct; 42 (4): 542-7
34. Hosoya K, Takeda K, Nishikimi T, et al. Force-length relationship in dogs as a measure of protective effect of imidapril on regional myocardial ischemia and reperfusion injury. Eur J Pharmacol 2000; 390 (1-2): 157-66
35. Fujiwara T, Yuasa H, Ogiku N, et al. Histopathological investigation on salt-loaded stroke-prone spontaneously hypertensive rats, whose biochemical parameters of renal dysfunction were ameliorated by administration of imidapril. Jpn J Pharmacol 1994; 66: 231-40
36. Hamaguchi A, Kim S, Wanibuchi H, et al. Imidapril inhibits increased transforming growth factor-β1 expression in remnant kidney model. Eur J Pharmacol 1997 Jul 16; 331: 27-30
37. Satonaka H, Suzuki E, Hayakawa H, et al. Long-term effect of imidapril hydrochloride compared with dilazep hydrochloride administration on blood pressure and renal function in patients with chronic glomerulonephritis. Int Heart J 2005 Jul; 46 (4): 701-10
38. Yoshitomi Y, Kojima S, Yano M, et al. Long-term effects of bisoprolol compared with imidapril on left ventricular remodeling after reperfusion in acute myocardial infarction: an angiographic study in patients with maintained vessel patency. Am Heart J 2000 Dec; 140 (6): E27 (1-7)
39. Soejima H, Ogawa H, Yasue H, et al. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997 May; 20: 441-5
40. Tokudome M, Uno T, Sato Y. Effects of imidapril treatment on insulin resistance in diabetic patients [in Japanese]. J Jpn Diabetes Soc 2003; 46 (8): 685-8
41. Arai T, Yoshimi N, Fujiwara H, et al. Serum substance P concentrations and silent aspiration in elderly patients with stroke [letter]. Neurology 2003 Dec 9; 61 (11): 1625-6
42. Arai T, Yasuda Y, Takaya T, et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and symptomless dysphagia [letter]. Chest 2000 Jun; 117 (6): 1819-20
43. Sakamoto KI, Sugimoto KI, Fujimura A. Different inhibition of enalaprilat and imidaprilat on bradykinin metabolizing enzymes. Life Sci 2000; 67 (18): 2159-65
44. Hosoya K, Ishimitsu T. Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. Cardiovasc Drug Rev 2002 Summer; 20 (2): 93-110
45. Harder S, Thürmann PA, Ungethüm W. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Br J Clin Pharmacol 1998 Apr; 45: 377-80
46. MacGregor GA. Expert report on the clinical documentation. Tanabe Seiyaku Co. Ltd, 1996. (Data on file)
47. Sabharwal NK, Swinburn J, Lahiri A, et al. Effect of imidapril and nifedipine on left ventricular hypertrophy in untreated hypertension. Clin Drug Invest 2005; 25 (6): 367-75
48. Takahashi M, Minatoguchi S, Nishigaki K, et al. Long-term and strict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients with essential hypertension: an evaluation using a novel indicator of burden on the left ventricle. Hypertens Res 2006 Feb; 29 (2): 89-94
49. Sasaguri M, Noda K, Tashiro E, et al. The regression of left ventricular hypertrophy by imidapril and the reduction of serum procollagen type III amino-terminal peptide in hypertensive patients. Hypertens Res 2000 Jul; 23: 317-22
50. Katayama S, Kikkawa R, Isogai S, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM) [published erratum appears in Diabetes Res Clin Pract 2002 Jul; 57 (1): 71]. Diabetes Res Clin Pract 2002 Feb; 55: 113-21
51. Hoogkamer JFW, Kleinbloesem CH, Nokhodian A, et al. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with chronic renal failure. Eur J Clin Pharmacol 1998 Mar; 54: 59-61
52. Hoogkamer JFW, Kleinbloesem CH, Nokhodian A, et al. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. Eur J Clin Pharmacol 1997 Feb; 51: 489-91
53. Hirota Y, Kawamura K, Ooyagi A. Phase I study of TA-6366 (I): single oral administration [in Japanese]. J Clin Ther Med 1992; 8: 507-22
54. Breithaupt-Grögler K, Ungethüm W, Meurer-Witt B, et al. Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothiazide, bisoprolol and nilvadipine. Eur J Clin Pharmacol 2001 Jul; 57: 275-84
55. Palma Gámiz JL, Pêgo M, Contreras EM, et al. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: The Iberian Multicenter Imidapril study on hypertension (IMISH). Clin Ther 2006 Dec; 28 (12): 2040-51
56. Zweiker R, Stoschitzky K, Maier R, et al. Efficacy and safety of the ACE-inhibitor imidapril in patients with essential hypertension. Acta Med Austriaca 2002; 29 (2): 72-6
57. Shionoiri H, Takasaki I, Minamisawa K, et al. Cough-challenge trial with a new angiotensin-converting enzyme inhibitor, imidapril. J Clin Pharmacol 1998 May; 38: 442-6
58. Liu G. Comparative study of hypotensive efficacy and the cough occurrence of imidapril versus benazepril [in Chinese]. Chin J Cardiol 2004 Apr; 32 (4): 304-7
59. Saruta T, Arakawa K, Iimura O, et al. Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res Clin Exp 1999 Sep; 22: 197-202
60. Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004 Aug; 4 (4): 267-70
61. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. National High Blood Pressure Education Program Coordinating Committee. JAMA 2003 May 21; 289 (19): 2560-72
62. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362 (9395): 1527-35
63. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351 (9118): 1755-62
64. Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005 Sep 13; 112 (11): 1651-62
65. Andersson OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow up study after two decades. BMJ 1998 Jul 18; 317 (7152): 167-71
66. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903-13
67. Laurent S. Guidelines from the British Hypertension Society: the lower the pressure the better. BMJ 2004 Mar 13; 328 (7440): 593-4
68. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. European Society of Hypertension-European Society of Cardiology Guidelines Committee [published erratum appears in J Hypertens 2003 Nov; 21 (11): 2203-4 and J Hypertens 2004 Feb; 22 (2): 435]. J Hypertens 2003 Jun; 21 (6): 1011-53
69. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004 Mar; 18 (3): 139-85
70. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. World Health Organization, International Society of Hypertension Writing Group. J Hypertens 2003 Nov; 21 (11): 1983-92
71. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000 Dec 9; 356 (9246): 1955-64
72. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003 May 21; 289 (19): 2534-44
73. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 Jun 27; 165 (12): 1410-9
74. Sever PS, Poulter NR, Elliott WJ, et al. Blood pressure reduction is not the only determinant of outcome. Circulation 2006 Jun 13; 113 (23): 2754-72
75. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004 Nov 27; 329 (7477): 1248-9
76. McDonald MA, Simpson SH, Ezekowitz JA, et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005 Oct 15; 331 (7521): 873-6
77. Verdecchia P, Angeli F, Gattobigio R, et al. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005 Nov; 26 (22): 2381-6
78. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens 2005 Dec; 23 (12): 2113-8
79. Volpe M, Tocci G, Savoia C. Angiotensin II receptor blockers and coronary artery disease: 'presumed innocents' [letter]. Eur Heart J 2006 Jun; 27 (12): 1506-7
80. Strauss MH, Hall AS, Tsuyuki RT, et al. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006 Aug 22; 114 (8): 838-54
81. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006 Aug 22; 114 (8): 838-54
82. Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006 Aug 22; 114 (8): 855-60
83. National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care. Partial update. London: Royal College of Physicians, 2006 [online]. Available from URL: http://www.nice.org.uk/download.aspx?o=CG034fullguideline [Accessed 2006 Aug 10]
84. Harvey JN. Diabetic nephropathy. BMJ 2002 Jul 13; 325 (7355): 59-60
85. National Institute for Clinical Excellence. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Aug 15]
86. Dolezal T. Imidapril in heart failure. J Renin Angiotensin Aldosterone Syst 2006 Sep 29; 7 (3): 146-54
87. Arai T, Yasuda Y, Tayaka. T, et al. ACE inhibitors and symptomless dysphagia [letter]. Lancet 1998; 352 (9122): 115-6
88. Marik PE, Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest 2003 Jul; 124 (1): 328-36
89. Arai T, Yasuda Y, Toshima S, et al. ACE inhibitors and pneumonia in elderly people [letter]. Lancet 1998 Dec 12; 352 (9144): 1937-8
90. Ohkubo T, Chapman N, Neal B, et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004 May 1; 169 (9): 1041-5